Nektar Therapeutics (NKTR) Misses Q1 EPS by 4c

Nektar Therapeutics (NASDAQ: NKTR) reported Q1 EPS of ($0.19), $0.04 worse than the analyst estimate of ($0.15). Revenue for the quarter came in at $21.6 million versus the consensus estimate of $14.49 million.

For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Rein Therapeutics Inc. (RNTX) Tops Q2 EPS by 39c
• Movano (MOVE) Misses Q2 EPS by 195c